TOP TEN perturbations for 39313_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39313_at
Selected probe(set): 211992_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39313_at (211992_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):3.4803352Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):3.2921572Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.908123Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.872589Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.4961967Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.4720478Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.4253063Number of Samples:2 / 4
| Experimental | R547 study 1 (24h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
pediatric septic shock study 3 (toddler; subclass A) / normal blood sample (toddler)
Relative Expression (log2-ratio):2.347536Number of Samples:4 / 18
| Experimental | pediatric septic shock study 3 (toddler; subclass A) |
| Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
| Control | normal blood sample (toddler) |
| Whole blood samples from toddlers (2 – 5 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study. |
endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) / endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic)
Relative Expression (log2-ratio):2.2706366Number of Samples:3 / 2
| Experimental | endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary adenocarcinoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-2.2563648Number of Samples:2 / 2
| Experimental | zalypsis study 2 |
| OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated OPM1 cell sample |
| OPM1 multiple myeloma cells untreated. |